Atossa Therapeutics (ATOS)
Develops oral (Z)-endoxifen for breast cancer and selected rare diseases.
$2.49
At close+0.07 (+2.89%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions34 holders · as of Mar 31, 2026 | 12.43% | 1.24M shares | |
| Insiders8 holders · as of May 14, 2026 | 2.14% | 213.4K shares | |
| Otherremainder | 85.43% | 8.53M shares |
9.98M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Institutions13F, as of Mar 31, 2026
34 holders · 1.24M shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 349.1K | 3.50% | May 15, 2026 | |
| Ameriprise Financial Inc | 255.1K | 2.56% | Jul 17, 2026 | |
| BlackRock, Inc. | 133.2K | 1.33% | May 13, 2026 | |
| Renaissance Technologies LLC | 109.0K | 1.09% | May 14, 2026 | |
| Geode Capital Management, LLC | 97.1K | 0.97% | May 15, 2026 | |
| UBS Group AG | 92.0K | 0.92% | May 5, 2026 | |
| Millennium Management LLC | 66.7K | 0.67% | May 15, 2026 | |
| Vanguard Fiduciary Trust Co | 52.2K | 0.52% | May 8, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.70% | Nov 8, 2024 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.